课题基金 / 基金详情

ACTG 243--PHASE II STUDY COMPARING ANTIRETROVIRAL THERAPY ALONE OR WITH ARA-C

ACTG 243--PHASE II STUDY COMPARING ANTIRETROVIRAL THERAPY ALONE OR WITH ARA-C
ACTG 243——比较单独抗逆转录病毒治疗或与 ARA-C 治疗的 II 期研究
批准号：
6246239
负责人：
HENRY S SACKS
金额：
$4.47万
依托单位：
MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-03-12 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6246239
关键词：
AIDS therapy HIV infections antiAIDS agent antiviral agents chemoprevention clinical research combination chemotherapy cytosine arabinoside drug screening /evaluation human morbidity human subject human therapy evaluation longitudinal human study nervous system disorder chemotherapy progressive multifocal leukoencephalopathy

项目摘要

项目成果

HENRY S SACKS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a randomized open-label study which will compare the efficacy of antiretroviral therapy vs. antiretroviral therapy plus cytosine arabinoside (Ara-C) in the prevention of death during study follow-up in HIV-infected individuals who have developed progressive multifocal leukoencelphalopathy (PML).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Meta-analysis of CAM therapies for HIV
Meta-analysis of CAM therapies for HIV
Meta-analysis of CAM therapies for HIV
Meta-analysis of CAM therapies for HIV
海外基金